DPS Group and TRIA Congratulate CRISPR Therapeutics on ISPE Facility of the Year Award

Company lauded for building flexible, digital manufacturing facility in Framingham, MA that can deliver on promise of innovation

BOSTON, MA/ACCESSWIRE/June 1, 2022/ DPS group, a privately-held global engineering, procurement, construction management and validation (EPCMV) company serving high-tech process industries, and design subsidiary TRIA, a partner-led architecture firm that focuses on science and technology organizations bringing new discoveries to market, congratulates CRISPR Therapeutics on being selected as the winner of the 2022 Facility of the Year Awards (FOYA) category for innovation by the International Society of Pharmaceutical Engineering (ISPE) for the CRISPR Therapeutics manufacturing facility in Framingham, Massachusetts. The ISPE Facility of the Year Awards are an annual program that recognizes cutting-edge projects that use innovative new technologies to improve product quality, reduce the cost of producing high-quality drugs, and demonstrate advances in carrying out projects.

“Driven by our unwavering commitment to meeting patient needs, we are proud to be recognized by ISPE as the 2022 Innovation Facility of the Year for our state-of-the-art manufacturing facility in Framingham, Massachusetts, which has been innovatively designed with flexibility and scale, said Stephen Kennedy, head of technology operations at CRISPR Therapeutics.

Innovation category winners exemplify the innovative application of process manufacturing techniques, innovative design concepts, new technologies and unique solutions that exemplify the next generation of new and existing pharmaceutical and biotechnology facilities that are agile, flexible, efficient. and efficient. This includes implementing off-the-shelf and custom-developed equipment that has delivered superior results, improved competitive position, and/or demonstrated imaginative collaboration with vendors/suppliers/manufacturers.

CRISPR Therapeutics leverages the CRISPR/Cas9 gene-editing platform to develop gene-based medicines for patients with serious diseases. The project received a FOYA Innovation Award based on the innovative design of the facility, which provides an end-to-end solution for production and filling operations.

“We are very grateful to all of our partners in this project. DPS did a great job engineering and designing the project and kept the team integrated and coordinated even throughout the COVID-19 pandemic,” added Brad Ebel, Framingham Site Manager at CRISPR Therapeutics. “We extend our congratulations to the entire team who worked on this rewarding project.”

The ISPE FOYA jury was impressed by the many facets of the application, including:

  • Digital systems and automation at all levels of the operation enable continuous monitoring and efficient product production and release;
  • A flexible usage model allows simultaneous production of multiple products at different stages of development;
  • Independent and/or redundant utilities supplying individual clean rooms enable continuous production without the need for facility-wide maintenance shutdown, and
  • Vaporized Hydrogen Peroxide (VHP) system to facilitate rapid product changeover and reduced use of environmentally harmful chemicals.

The CRISPR Therapeutics manufacturing facility was thoughtfully and innovatively designed, and the facility’s ability to catalyze the technology’s promise impressed the judges. The facility is unique in that it uses a compact design with multiple independent production suites, each capable of producing a different product at a different stage of development while maintaining strict product segregation. The judges were particularly impressed with the use of a fully integrated digital stack that allows a small on-site warehouse to be continuously supplied from external sources while maintaining uninterrupted production and test operations. While the design of the facility was based on fundamental good engineering practice, there was an intentionality in the flexibility of the facility that the committee found very innovative.

Following a series of user group meetings and leadership workshops, DPS was able to glean operational needs for CRISPR which were then used to develop a first-in-class cGMP design for cell therapy and production. of AAV. The DPS team has worked with CRISPR Therapeutics on numerous layouts and process design scenarios to create spaces that will be flexible for years to come. DPS Group’s in-house experts were able to advise CRISPR on industry best practices across all engineering disciplines throughout schematic design, design development, and construction administration. Working with the CRISPR team as business needs evolved was critical to the overall success of the project.

Through group visualization sessions, leadership workshops, and focus groups, TRIA identified spatial and aesthetic needs for quality labs and offices. TRIA’s laboratory and workplace design expertise and insights gathered during the visioning, programming and planning process enabled the creation of an effective and unique design. Open plan offices and amenity spaces promote interaction and collaboration. The design embraces the abundant natural light and exposed steel structure of the building. Glass walls are incorporated throughout to provide transparency, natural light, and a connection between the office and the manufacturing space.

Supply partners and key participants include:

  • Manufacturer/Owner: CRISPR Therapeutics
  • Engineer: Groupe DPS Inc.
  • Architect: TRIA Design
  • Owners Representative (OPM): Leggat McCall Properties LLC
  • Construction Manager/General Contractor: Commodore Builders LLC
  • Structural engineer: Pare Corp.

Serving high-tech industries worldwide, DPS Group provides full-service engineering across a range of disciplines including project management, procurement, design, construction management, health management and Safety, Commissioning, Qualification and Validation (CQV) and Installation Begin.

About DPS Group

DPS Group is a global engineering, consulting and project management company serving high technology industries worldwide. DPS provides services to its clients across the entire engineering and construction value chain, including feasibility studies, concepts, consulting, architecture, engineering, procurement, construction, commissioning, qualification and validation as well as customer-side technical services.

DPS applies its extensive process engineering expertise built over 47 years, as well as significant Lean construction experience to help customers in high-end process industries such as pharmaceuticals, biotech and semiconductors deliver manufacturing facilities quickly, safely and affordably. What sets the company apart are the partnerships it builds with its customers through a fundamental understanding of their business and its own agility, flexibility, original thinking and high caliber people.

DPS has grown significantly in recent years and now employs over 2,500 people in 18 offices and at customer sites in Ireland, UK, Netherlands, Belgium, Sweden, Switzerland, Israel, in Singapore, Saudi Arabia and the United States. For more information, visit www.dpsgroupglobal.com.

About TRIA

TRIA is a full-service architectural firm that values ​​client relationships above all else. The firm’s principal-focused approach puts our leadership team at the table of client decision makers, working together to envision success, solve problems and deliver exceptional results. Our lab design and corporate interiors teams strive to learn each client’s unique DNA, and in doing so, we create efficient and energizing spaces that reflect a company’s culture and promote the innovation. At TRIA, we design spaces that enable business success and advance new discoveries – in the lab, around the office and beyond. Visit us on the web at https://tria.design

Media Contact:

Susan Shelby, FSMPS, CPSM
Rhino RP
[email protected]

THE SOURCE: DPS Group – Boston

See the source version on accesswire.com:

Comments are closed.